FinancingNK cell therapy company NK:IO raises seed...British NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m. more ➔
DealAlnylam in US$2.8bn biobucks deal with Roc...siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive. T more ➔
IPResistance blocker of immune checkpoint in...The EPO has granted a patent to Domain Therapeutics Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system. more ➔
Alzheimer'sLilly presents impressing results for Alzh...Eli Lilly’s Alzheimer’s drug donanemab has speedy removed amyloid plaques in a pivotal Phase III trail halting disease progression for one year in half of patients. more ➔
ScienceBiomethane fuel offers negative carbon foo...Although the EU Commission wants to abolish the internal combustion engine in individual transport through eMobility, biofuels are far from dead, according to a new study. more ➔
RecyclingCarbios raises €141m to boost enzymatic...In an oversubscribed capital increase, Carbios SAS has raised €141m, the largest on Euronext growth since 2015. more ➔
FinancingEG 427 expands Series A closing to €18mParis-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at €18m raising additional €5m in the final closing. more ➔
FinancingSeed money for unique topical hair growth...Mallia Therapeutics GmbH has raised seed money to accelerate preclinical research and start Phase I testing of a baldness cure with unique MOA named soluble CD83. more ➔
CollaborationEvotec earns US$40m in global licence deal...German CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities. more ➔
DealNanobiotix SA licences NBTXR3 to J&JParis-based Nanobiotix SA has signed a potential US$1.8bn oncology deal with Janssen Pharmaceutica NV for the global commercialisation rights of its radioenhancer NBTXR3. more ➔
